Search results
Pfizer pauses phase 3 dosing in gene therapy trial after young boy's death
FierceBiotech· 9 hours agoA young boy with Duchenne muscular dystrophy (DMD) participating in Pfizer’s phase 2 gene therapy...
Do These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend
Simply Wall St. via Yahoo Finance· 4 days agoReaders hoping to buy Pfizer Inc. (NYSE:PFE) for its dividend will need to make their move shortly,...
Pfizer Pauses Gene Therapy Trial for Muscle Disease After Death
Bloomberg· 9 hours agoPfizer Inc. paused a study of an experimental gene therapy for muscular dystrophy after a child who...
Pfizer wants the $75 mln left from SAC Capital’s insider trading settlement with SEC
Reuters· 9 hours agoPharma company Pfizer told a New York federal judge on Monday that it is entitled to recoup about...
Patient dies in Pfizer study of Duchenne gene therapy
BioPharma Dive via Yahoo Finance· 12 hours agoPfizer said the patient, a young boy who was treated earlier last year, had died suddenly. The...
Pfizer reports patient death in Duchenne gene therapy study
Reuters via Yahoo News· 8 hours ago(Reuters) -A young patient died due to cardiac arrest after receiving Pfizer's experimental gene...
AstraZeneca withdrawing Covid vaccine, months after admitting rare side effect
The Telegraph via Yahoo News· 9 hours agoThe Oxford-AstraZeneca Covid vaccine is being withdrawn worldwide, months after the pharmaceutical...
Is Pfizer Stock Fully Valued At $28?
Forbes· 1 day agoPfizer (NYSE: PFE) reported its Q1 results last week, with revenues and earnings beating the street estimates.
Pfizer First Quarter 2024 Earnings: Beats Expectations
Simply Wall St. via Yahoo Finance· 18 hours agoPfizer (NYSE:PFE) First Quarter 2024 Results Key Financial Results Revenue: US$14.9b (down 19% from...
Pfizer Is Adding a Wall Street Analyst to Its C-Suite. What He Thinks the Company Needs to Do.
Barrons.com· 1 day agoSTOCK ALERT Andrew Baum, the prominent Wall Street drug company analyst, has never been much of a...